Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to ...

Vi seroprotection rates (≥ 1 µg/mL) of 85.2% and 84.9% after 28 days ... Conclusions: The combined HA/Vi vaccine, Viatim, had equivalent tolerability and safety and was as rapidly immunogenic ...

For other vaccine antigens, namely ... Intergroup Comparison* Noninferiority Margin Diphtheria 0.01–0.1 IU/mL % of subjects with antidiphtheria antibodies ≥0.1 IU/ml (≥1.0 IU/mL in ...

a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines ... 2,900 IU/mL for placebo at Day 28. • RSV-B Specific Antibodies: SCB-1019 (bivalent RSV-A/B) ...

HAV vaccination was highly immunogenic among virologically suppressed patients with HIV and those on immunosuppressive monotherapy.

The cold and flu are respiratory illnesses caused by different viruses. Some cold and flu symptoms may overlap, but there are ...

The Ministry of Health has approved Moderna's updated COVID vaccines, which target the new JN1 variant of the virus.

Regulating drug discovery and pharmaceutical manufacturing, the FDA ensures the safety and effectiveness of innovative ...

Revaccination at 12 months with the investigational respiratory syncytial virus (RSV) vaccine mRNA-1345 is well tolerated and supported for eligible older adults, according to study results presented ...

Rigel Pharmaceuticals, Inc. today announced that it will report its third quarter 2024 financial results after market close on Thursday, November 7, 2024. Rigel senior management will follow the ...